Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) has shared an update.
NeuroScientific Biopharmaceuticals Limited has announced significant progress in its clinical development efforts for StemSmart™, a treatment for Crohn’s disease. The company has received approval from the TGA for its initial patients in the Special Access Program, a crucial step towards a Phase 2 Clinical Trial. The appointment of Dr. Catherine Cole as Chief Medical Officer and Nathan Smith as CEO brings valuable expertise to the company, enhancing its capabilities in clinical development and manufacturing. Additionally, NSB has partnered with Q-Gen Cell Therapies to scale its manufacturing process, positioning the company for future clinical trials and commercialization.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Limited is an innovative Australian biotechnology company focused on developing novel technologies for immune-mediated inflammatory diseases. The company is engaged in advancing its StemSmart™ MSC technology, which is targeted at treating severe and treatment-resistant forms of Crohn’s disease.
Average Trading Volume: 365,312
Technical Sentiment Signal: Buy
Current Market Cap: A$36.58M
For an in-depth examination of NSB stock, go to TipRanks’ Overview page.